TELA Key Statistics, Chart & Performance
The current stock price of TELA is 1.15 USD. In the past month the price decreased by -2.54%. In the past year, price decreased by -61.28%.
TELA Latest News, Press Relases and Analysis
TELA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.71 | 16.18B | ||
| SOLV | SOLVENTUM CORP | 14.38 | 14.82B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.26 | 11.28B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.43 | 4.95B | ||
| LNTH | LANTHEUS HOLDINGS INC | 10.62 | 4.20B | ||
| HAE | HAEMONETICS CORP/MASS | 17.49 | 3.93B | ||
| ICUI | ICU MEDICAL INC | 17.9 | 3.52B | ||
| XRAY | DENTSPLY SIRONA INC | 7.12 | 2.24B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.16 | 1.67B | ||
| NEOG | NEOGEN CORP | 19.93 | 1.30B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.26B | ||
| EMBC | EMBECTA CORP | 3.94 | 683.98M |
Related stock screener links
About TELA
Company Profile
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Company Info
TELA BIO INC
1 Great Valley Parkway, Suite 24
Malvern PENNSYLVANIA 19355 US
CEO: Antony Koblish
Employees: 209
Phone: 14843202930
TELA BIO INC / TELA FAQ
Can you describe the business of TELA BIO INC?
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
What is the current price of TELA stock?
The current stock price of TELA is 1.15 USD. The price increased by 0.88% in the last trading session.
What is the dividend status of TELA BIO INC?
TELA does not pay a dividend.
What is the ChartMill technical and fundamental rating of TELA stock?
TELA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for TELA BIO INC?
The Revenue of TELA BIO INC (TELA) is expected to grow by 7.65% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of TELA stock?
TELA BIO INC (TELA) has a market capitalization of 50.34M USD. This makes TELA a Micro Cap stock.
What is the Short Interest ratio of TELA BIO INC (TELA) stock?
The outstanding short interest for TELA BIO INC (TELA) is 1.04% of its float.
TELA Technical Analysis
TELA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TELA. TELA has a bad profitability rating. Also its financial health evaluation is rather negative.
TELA Financial Highlights
Over the last trailing twelve months TELA reported a non-GAAP Earnings per Share(EPS) of -0.89. The EPS increased by 47.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.32% | ||
| ROE | -2504.69% | ||
| Debt/Equity | 26.65 |
TELA Forecast & Estimates
11 analysts have analysed TELA and the average price target is 3.52 USD. This implies a price increase of 206% is expected in the next year compared to the current price of 1.15.
For the next year, analysts expect an EPS growth of 38.65% and a revenue growth 7.65% for TELA